WESTPORT, Conn., Dec. 10, 2010 /PRNewswire/ -- Advanced BioHealing, Inc. (ABH), a leader in commercializing cell-based therapies and delivering on the promise of regenerative medicine, today announced the appointment of Kevin C. O'Boyle, as Senior Vice President and Chief Financial Officer.
"We are pleased to welcome Kevin to our team as we continue to build a leading commercial regenerative medicine organization," said Kevin Rakin, Chairman and Chief Executive Officer for ABH. "Kevin has an outstanding track record as CFO of companies executing high-growth strategies, focused on both organic and external opportunities, and accessing the equity markets."
ABH has grown revenue from zero in 2006 to over $130 million in 2010 and today employs more than 350 professionals. These strong results are based on growing demand for its FDA-approved product Dermagraft® for the treatment of diabetic foot ulcers.
"I am excited about joining the exceptional team at Advanced BioHealing," said Mr. O'Boyle. "Advanced BioHealing is a well-established leader in the field of regenerative medicine with the ability to improve patient lives with its cell-based therapy. I look forward to bringing my leadership experience to the company as it moves into its next phase of commercial growth."
Mr. O'Boyle has 15 years experience in the healthcare industry. From January 2003 until December 2009, Mr. O'Boyle served as the Chief Financial Officer of NuVasive, Inc., a medical device company focused on spinal applications, which completed its initial public offering in May 2004. He joined NuVasive when it had less than $30 million in annual revenue and was a key member of the management team that grew the business to more than $400 million in annual revenue. Prior to that time, Mr. O'Boyle served in various positions during his six years with ChromaVision Medical Systems, Inc., a publicly-held medical device company specializing in the oncology market, including as its Chief Financial Officer and Chief Operating Officer. Mr. O'Boyle currently serves on the boards of GenMark Diagnostics, Inc., a publicly traded molecular diagnostics company, and Tornier, BV, a privately held global orthopedics company.
Mr. O'Boyle received his Bachelor of Science in Accounting from the Rochester Institute of Technology and successfully completed the Executive Management Program at the University of California Los Angeles, John E. Anderson Graduate Business School.